Cellino Biotech Inc

Hunterian Medicine LLC is a gene editing company based in Cambridge, MA, focused on curing genetic diseases by correcting DNA mutations using innovative CRISPR delivery technology. Their patented platform addresses the significant delivery challenges associated with CRISPR, enabling efficient and targeted delivery through a single adeno-associated virus (AAV). With the potential to develop cures for numerous genetic disorders that currently lack FDA-approved treatments, Hunterian Medicine aims to revolutionize the field of genetic therapy. Their technology allows scientists to target over a billion more regions in the human genome than existing methods, paving the way for the next generation of CRISPR-based therapeutics. Generated from the website

Kytopen Corp, based in Cambridge, MA, is dedicated to enhancing patient access to next-generation living medicines through innovative genome engineering platforms. Their non-viral gene delivery technology addresses cell therapy manufacturing challenges, streamlining drug discovery and optimization processes. The company's flagship Flowfect platform combines continuous fluid flow and electric fields to deliver payloads efficiently to billions of cells within minutes, enabling scalable cell engineering from the discovery stage to large-volume production. By facilitating high-throughput experimentation and predictive scaling, Kytopen empowers researchers to optimize gene delivery while retaining cell functionality. Generated from the website

Parallel Bio, based in Cambridge, MA, is pioneering the use of immune organoids and artificial intelligence to develop innovative immunotherapies that are safe and effective for human patients from the outset. By creating in-vitro replicas of human lymph nodes, the company aims to replace traditional animal models in drug discovery, significantly reducing development time and costs. The company's mission is to revolutionize the pharmaceutical industry by providing a more ethical and efficient approach to drug development, enabling faster access to therapies for a diverse range of diseases. With a focus on harnessing the immune system's capabilities, Parallel Bio is positioned to transform the future of medicine and improve health outcomes globally. Generated from the website